Akebia Therapeutics (AKBA) Change in Account Payables (2015 - 2026)

Akebia Therapeutics (AKBA) has 12 years of Change in Account Payables data on file, last reported at -$7.8 million in Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$7.8 million, down 248.79% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.5 million (down 163.44% YoY), and the FY2025 annual result was $3.1 million, up 325.95% from the prior year.
• Change in Account Payables eased to -$7.8 million in Q1 2026 per AKBA's latest filing, from $10.4 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $18.9 million in Q4 2022 and troughed at -$9.0 million in Q1 2023.
• A 5-year average of -$577470.6 and a median of -$2.2 million in 2025 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2022 and 2026: Change in Account Payables soared 491.65% in 2022, then tumbled 248.79% in 2026.
• A 5-year view of Change in Account Payables shows it stood at $18.9 million in 2022, then slumped by 76.2% to $4.5 million in 2023, then plunged by 46.84% to $2.4 million in 2024, then jumped by 335.21% to $10.4 million in 2025, then slumped by 174.79% to -$7.8 million in 2026.
• Business Quant data shows AKBA's Change in Account Payables at -$7.8 million in Q1 2026, $10.4 million in Q4 2025, and -$8.8 million in Q3 2025.